…to provide efficacy across key measures of disease activity in patients with highly active RMS, including disability progression, annualized relapse rate and magnetic resonance imaging (MRI) activity. “Multiple Sclerosis (MS)…
Content Section:
News Posts
This annual symposium is aimed primarily at clinicians who treat patients with diseases of the peripheral nervous system and muscle, especially general adult neurologists but also clinical neurophysiologists, paediatric neurologists…
Content Section:
Event News
…with disease-modifying therapy, defined as one relapse in the previous year and MRI evidence of disease activity.3 This is the first MS disease-modifying therapy that has gone straight to a…
Content Section:
News Posts
…register in Ireland. She described how little progress had been made on developing disease-modifying agents, but underscored how the multiple disease mechanisms underlying MND would be unlikely to uniformly respond…
Content Section:
Conference Reports
…programme against brain diseases’, B Norrving [WSO] on ‘stroke as a brain disease in ICD 11 – what does it mean?’, R Sacco [AAN) on ‘Stroke prevention and Brain Health…
Content Section:
Conference Reports
European Commission approves PONVORYTM ▼ (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features The…
Content Section:
News Posts
…studies with FDG-PET or SPECT are advocated in suspected Alzheimer’s disease and frontotemporal dementia undiagnosed by other methods, although neither achieved very large LRs, and FP-CIT-SPECT or MIBG cardiac scintigraphy…
Content Section:
Articles
…of astrocytes in CNS conditions, such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, epilepsy, pain disorders, and neuropsychiatric conditions. With the introduction of ioAstrocytes, scientists now have access to defined,…
Content Section:
News Posts